Search Results

By Caroline Helwick  / Tuesday, October 22, 2013 11:35 AM

New Nanopharmaceutical May Be Able to Overcome Resistance to Antiangiogenic Treatment

The nanopharmaceutical CRLX101, a novel inhibitor of topoisomerase-1 and hypoxia-inducible factor (HIF)-1 alpha, may be capable of overcoming resistance of tumors to antiangiogenic agents, according to preclinical and early clinical studies that have evaluated CRLX101 in combination with...